Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF (Jinyouli) in Elderly Lymphoma Patients
NCT03870412Unknown
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegylated granulocyte colony-stimulating factor in neutropenia and febrile neutropenia (FN), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Incidence of febrile neutropenia in cycles 1 to 6. Status: unknown.
02
Drugs
pegylated granulocyte colony-stimulating factor
03
Conditions
neutropeniafebrile neutropenia (FN)
Beyond the preview
Go deeper on NCT03870412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870412.